5/6/2013

Ferring Pharmaceuticals has started enrolling patients with chronic idiopathic constipation for two late-stage trials of its experimental drug elobixibat. The study, which will involve almost 1,700 patients, will be carried out at about 200 centers globally.

Related Summaries